Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Aeglea BioTherapeutics stock in Canada | $7.7
Own Aeglea BioTherapeutics shares in just a few minutes.
Aeglea BioTherapeutics is a biotechnology business based in the US. Aeglea BioTherapeutics stocks (AGLE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.13 – an increase of 8.6% over the previous week. Aeglea BioTherapeutics employs 91 staff and has a trailing 12-month revenue of around $13.7 million.
How to buy Aeglea BioTherapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGLE in this case.
- Research Aeglea BioTherapeutics stocks. The platform should provide the latest information available.
- Buy your Aeglea BioTherapeutics stocks. It's that simple.
Is it a good time to buy Aeglea BioTherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Aeglea BioTherapeutics?
- Has coronavirus impacted Aeglea BioTherapeutics shares?
- Aeglea BioTherapeutics shares summary
- Compare share dealing platforms
- Is Aeglea BioTherapeutics stock a buy or sell?
- Aeglea BioTherapeutics performance over time
- Can I short Aeglea BioTherapeutics shares?
- Aeglea BioTherapeutics's financials
- How volatile are Aeglea BioTherapeutics shares?
- Does Aeglea BioTherapeutics pay a dividend?
- Other common questions
How has Coronavirus impacted Aeglea BioTherapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Aeglea BioTherapeutics's stock price has had significant negative movement.
Its last market close was $7.7, which is 2.16% down on its pre-crash value of $7.87 and 120.00% up on the lowest point reached during the March crash when the stocks fell as low as $3.5.
If you had bought $1,000 worth of Aeglea BioTherapeutics stocks at the start of February 2020, those stocks would have been worth $557.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,029.41.
Aeglea BioTherapeutics stock priceUse our graph to track the performance of AGLE stocks over time.
Aeglea BioTherapeutics stocks at a glance
|Latest market close||$7.7|
|52-week range||$5.82 - $9.9|
|50-day moving average||$6.846|
|200-day moving average||$7.1986|
|Wall St. target price||$14.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.017|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Aeglea BioTherapeutics price performance over time
|1 week (2021-09-16)||8.60%|
|1 month (2021-08-23)||7.84%|
|3 months (2021-06-23)||17.92%|
|6 months (2021-03-23)||-9.52%|
|1 year (2020-09-23)||11.92%|
|2 years (2019-09-23)||-6.10%|
|3 years (2018-09-21)||-15.94%|
|5 years (2016-09-23)||18.64%|
Aeglea BioTherapeutics financials
|Revenue TTM||USD$13.7 million|
|Gross profit TTM||USD$-59,638,000|
|Return on assets TTM||-25.72%|
|Return on equity TTM||-48.51%|
|Market capitalisation||USD$366.5 million|
TTM: trailing 12 months
How to short and sell Aeglea BioTherapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "AGLE.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 1.0 million Aeglea BioTherapeutics stocks held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 2.3% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics stocks can be evaluated.
Aeglea BioTherapeutics's "short interest ratio" (SIR)
Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics stocks currently shorted divided by the average quantity of Aeglea BioTherapeutics stocks traded daily (recently around 127097.72727273). Aeglea BioTherapeutics's SIR currently stands at 7.92. In other words for every 100,000 Aeglea BioTherapeutics stocks traded daily on the market, roughly 7920 stocks are currently held short.
However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics stocks, or, against the total number of tradable Aeglea BioTherapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Aeglea BioTherapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0308% of the tradable stocks (for every 100,000 tradable Aeglea BioTherapeutics stocks, roughly 31 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Aeglea BioTherapeutics.
Find out more about how you can short Aeglea BioTherapeutics stock.
Aeglea BioTherapeutics stock dividends
We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Aeglea BioTherapeutics stock price volatility
Over the last 12 months, Aeglea BioTherapeutics's stocks have ranged in value from as little as $5.82 up to $9.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6681. This would suggest that Aeglea BioTherapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea BioTherapeutics overview
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Stocks similar to Aeglea BioTherapeutics
Aeglea BioTherapeutics in the news
Aeglea BioTherapeutics : HC Wainwright 23rd Annual Global Investment Conference
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
Frequently asked questions
More on investing
Everything we know about the Perion Network IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
More guides on Finder
How to buy Evergrande Group stock in Canada | $2.27
Steps to owning and managing China Evergrande Group shares from Canada.
How to buy Planet Labs (PL) stock in Canada when it goes public
Everything we know about the Planet Labs IPO, plus information on how to buy in.
How to buy Impossible Foods stock in Canada when it goes public
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
How to buy Samsara stock in Canada when it goes public
Everything we know about the Samsara IPO, plus information on how to buy in.
How to buy Allbirds (BIRD) stock in Canada when it goes public
Everything we know about the Allbirds IPO, plus information on how to buy in.
How to buy Smooth Love Potion (SLP) in Canada
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
How to buy OnlyFans stock in Canada when it goes public
Everything we know about the OnlyFans IPO, plus information on how to buy in.
How to buy Vinco Ventures stock in Canada | $6.57
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
How to buy Weber stock in Canada | $14.9
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
How to buy Chobani stock in Canada when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.